Trial · NCT07893249
Individual Variability in Energy Compensation After a 12-Week Supervised Exercise Intervention
NCT07893249, Not applicable, Not yet recruiting, Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Individual Variability in Energy Compensation After a 12-Week Supervised Exercise Intervention. Trials, record NCT07893249. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07893249
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Individual Variability in Energy Compensation After a 12-Week Supervised Exercise Intervention
- NCT number
- NCT07893249
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 150 participants, estimated
- Lead sponsor
- Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
- Conditions
- Physical Inactivity, Overweight, Obesity
- Interventions
- Supervised Aerobic Exercise Programme
- First posted
- 2026-10-23
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes47
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Energy compensation after the 12-week supervised exercise intervention | Baseline to Week 12 | Exercise energy compensation (ExEC), expressed in percentage, will be calculated as \[(ExEE plus change in body energy stores) divided by ExEE\] multiplied by 100. ExEE will be calculated from completed supervised exercise sessions. Change in body energy stores will be derived from changes in fat mass and fat-free mass between baseline and Week 12 and divided by the intervention duration. A value of 0% indicates no compensation, whereas 100% indicates complete compensation for the exercise-induced energy expenditure. |
| Secondary | Change in body weight | Weekly from baseline through Week 12, with a follow-up assessment at Week 24 (12 weeks after completion of the intervention). | Difference in measured body weight in kilograms relative to baseline. |
| Secondary | Change in body composition | Baseline, Week 12, and Week 24 (12 weeks after completion of the intervention). | Difference in body composition will be measured by the prespecified body-composition method. Dual-energy X-ray absorptiometry will be used for the principal endpoint if confirmed; bioelectrical impedance will be used for interim monitoring. Changes in abdominal subcutaneous adipose tissue, visceral adipose tissue, organ-specific fat depots, and the volume or size of prespecified organs will be quantified using magnetic resonance imaging.Changes at Week 12 and 24 will be assessed relative to baseline. |
| Secondary | Change in energy expenditure | Baseline, Week 12, and Week 24 (12 weeks after completion of the intervention). | Difference in average daily total energy expenditure will be measured using doubly labeled water. Changes in 24-hour energy expenditure, sleeping energy expenditure, resting energy expenditure, and the thermic effect of food will be measured by whole-room indirect calorimetry in a human metabolic chamber. Exercise energy expenditure and excess post-exercise oxygen consumption (EPOC) will be assessed by indirect calorimetry using a COSMED. Changes at Week 12 and 24 will be assessed relative to baseline. |
| Secondary | Change in ad libitum energy intake | Baseline, Week 12, and Week 24 (12 weeks after completion of the intervention). | Difference in energy intake, measured during the free-living conditions and laboratory meal assessment. Changes at Week 12 and Week 24 will be assessed relative to baseline. |
| Secondary | Change in hunger rating | Baseline, Week 12, and Week 24 (12 weeks after completion of the intervention). | Hunger will be assessed using a 100-mm visual analogue scale in response to the question "How hungry do you feel?" The scale is anchored by "I am not hungry at all" at 0 mm and "I have never been more hungry" at 100 mm. The distance from the left end of the scale to the participant's mark will be measured in millimeters. The mean of all valid hunger ratings collected during each assessment period will be calculated. Higher scores indicate greater perceived hunger. Changes at Week 12 and Week 24 will be assessed relative to baseline. |
| Secondary | Change in neural responses to food-related stimuli | Baseline, Week 12, and Week 24 (12 weeks after completion of the intervention). | Neural activation characteristics of reward-related and energy homeostasis-regulating brain regions during the selection of foods with varying energy densities and macronutrient compositions, assessed by fMRI and EEG.Changes at Week 12 and 24 will be assessed relative to baseline. |
| Secondary | Change in maximal oxygen uptake | Monthly from baseline through Week 12, with a follow-up assessment at Week 24 (12 weeks after completion of the intervention). | Maximal oxygen uptake will be measured during a graded treadmill exercise test using a respiratory gas-analysis system. Relative maximal oxygen uptake will be expressed in mL/kg/min. Changes at each post-baseline assessment will be evaluated relative to baseline. |
| Secondary | Change in free-living physical activity | Baseline, Week 12, and Week 24 (12 weeks after completion of the intervention). | Difference in accelerometer-derived physical activity using prespecified valid-wear criteria. Changes at Week 12 and 24 will be assessed relative to baseline. |
| Secondary | Change in mean interstitial glucose | Baseline, Week 12, and Week 24 (12 weeks after completion of the intervention). | Mean interstitial glucose will be calculated over the valid continuous glucose monitoring period and expressed in mmol/L. Changes at Week 12 and Week 24 will be assessed relative to baseline. |
1 to 10 of 47Source ClinicalTrials.gov
See all 47 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07893249
GET https://conductscience.org/api/trials/v1/NCT07893249/registered?page=2